A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression
- 31 October 1994
- journal article
- clinical trial
- Published by Elsevier in Journal of Affective Disorders
- Vol. 32 (2) , 105-114
- https://doi.org/10.1016/0165-0327(94)90068-x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Brofaromine in elderly major depressed patients — a comparative trial versus imipramineEuropean Neuropsychopharmacology, 1993
- The Selective Reversible Monoamine Oxidase-A Inhibitor Brofaromine and SleepJournal of Clinical Psychopharmacology, 1993
- Monoamine oxidase inhibitors in resistant major depression: A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressantsJournal of Affective Disorders, 1993
- Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.BMJ, 1993
- Brofaromine in major depressed patients: A controlled clinical trial versus Imipramine and open follow-up of up to one yearJournal of Affective Disorders, 1992
- Tolerability and antidepressive effect of brofaromine, a short-acting reversible MAO inhibitor — an open studyEuropean Neuropsychopharmacology, 1991
- Brofaromine vs. maprotiline plus lithium in treatment-resistant depressed outpatientsPsychiatry Research, 1991
- Brofaromine - a Selective, Reversible, and Short-Acting MAO-A Inhibitor: Review of the Pharmacological and Clinical FindingsPharmacopsychiatry, 1991
- QUANTITATIVE RATING OF DEPRESSIVE STATESActa Psychiatrica Scandinavica, 1975
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960